Perioperative chemotherapy is a standard option for treatment of patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC). This study aimed to assess the superiority of PAXG (cisplatin, nab-paclitaxel, capecitabine, and gemcitabine) over mFOLFIRINOX (modified fluorouracil, leucovorin, irinotecan, and oxaliplatin) in this population.

Climate change inflicts substantial economic damage on developing African nations, threatening progress towards the UN Sustainable Development Goals. There are synergies between actions needed to tackle climate change and other ongoing development priorities for Africa, including infectious disease control, facilitating clean energy access, reducing air pollution, tackling malnutrition and food insecurity, and providing universal health coverage. Action to protect human health against climate change needs to be integrated into all systems that are responsible for delivering essential services and implementing policies across all sectors that underpin the attainment of key development priorities for Africa. These systems include the Sustainable Development Goals and the African Union's 2063 Agenda for building The Africa We Want, and the ongoing negotiations and work programmes in the UN Framework Convention on Climate Change. Adequate stocktaking of and access to robust data and scientific evidence is needed to support this effort and guide priorities for policies that protect and promote health and for monitoring progress over time. In response to this need, the Lancet Countdown is launching a new initiative to bring together a transdisciplinary research collaboration to help build regional capacity, strengthen existing networks, generate evidence, and mobilise data across numerous domains at the climate change and health nexus in Africa.

Adequate pain control is essential; however, acute pain is often undertreated in prehospital care. This study aimed to evaluate three analgesic regimens for treating acute pain in an ambulance setting.

Obesity is a chronic disease that significantly contributes to type 2 diabetes and its complications. We aimed to evaluate orforglipron, an oral small-molecule (non-peptide) GLP-1 receptor agonist, for obesity treatment in adults with type 2 diabetes.